We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
We have identified you may not be viewing TRAVAX optimally because the browser you are using is unsupported - click here.
Measles remains widespread (endemic) in many countries worldwide, including Europe. Globally, health services and national vaccination programmes have been severely impacted by the COVID-19 pandemic, resulting in a risk of increasing numbers of measles outbreaks.
Measles is a highly infectious viral infection spread via airborne or droplet transmission. Symptoms include fever, rash, cough, coryza or conjunctivitis and may lead to serious and potentially life-threatening complications in some people.
Measles is most common in young children, but all ages are at risk if they have not been fully vaccinated or had prior measles infection.
Travel may increase an individual’s risk of exposure to measles virus, and facilitate the spread of disease to unvaccinated and susceptible populations. The travel consultation provides a valuable opportunity to ensure individuals are protected against measles, mumps and rubella (MMR) viruses. Two doses of MMR vaccine, at least one month apart, are required to give adequate protection.
Consider vaccinating:
Check that children are up to date with the UK Vaccination Schedule (two doses of MMR vaccine around 12-13 months, and before starting school at around 3 years 4 months of age).
See the TRAVAX Measles, Mumps and Rubella page for further information.
